Preimplantation genetic diagnosis (PGD) refers to an ancillary technique to in-vitro fertilization (IVF) that is used for the detection of genetic or inheritable diseases before an embryo is implanted. Preimplantation genetic diagnosis can be performed for the screening of a large number of medical conditions such as Down’s syndrome and a variety of physiological abnormalities. The rising awareness among patients regarding the benefits of PGD techniques, coupled with the growing prevalence of genetic diseases among children, is leading to an increased demand for preimplantation diagnosis methods and IVF procedures. Studies have demonstrated the high rate of successful pregnancy when IVF procedures are combined with PGD screenings, a factor that has heightened the acceptance regarding PGD techniques in the global market.
Browse Full Global Preimplantation Genetic Diagnosis Market Report with TOC :http://www.mrrse.com/asia-preimplantation-genetic-diagnosis-market
Demand for preimplantation genetic diagnosis techniques is, however, restricted to a certain extent by the regulations governing infertility techniques across different countries. In Asia, for instance,
Procedures such as PGD for gender selection and human leukocyte antigen (HLA) typing are banned, whereas these procedures are regulated in the U.S. and some parts of the European Union.
A recent market research report examining the Asia market for preimplantation genetic diagnosis published by Transparency Market Research states that the market will expand at a positive 6.8% CAGR from 2015 through 2023. The market, which had a valuation of US$ 16.0 mn in 2014, is projected to rise to US$ 28.8 mn by 2023.
Rising Numbers of IVF Procedures to Propel Asia Preimplantation Genetic Diagnosis Market
Asia is the home to some of the world’s most prominent developing and populated countries. Major developing countries such as China, India, Vietnam, Israel, Singapore, and Indonesia offer vast growth opportunities for the PGD market, majorly owing to three factors: the rising awareness about genetic disorders, increased expenditure on healthcare, and the rising rate of infertility and the consequent rise in IVF procedures.
Strengthening economies and rising disposable incomes directly relate to increased expenditure on several aspects, one of which is healthcare. Combine to this the rising awareness regarding the increased prevalence of genetic disorders and the willingness of expectant parents to spend money for ensuring that their babies are not carriers of a genetic disorder, and the healthy growth prospects of the PGD market in Asia become obvious.
Browse the full Press Release of Global Preimplantation Genetic Diagnosis Market at http://www.mrrse.com/asia-preimplantation-genetic-diagnosis-industry
The rising rate of infertility among the Asian population is another prominent factor that is propelling the market for preimplantation genetic diagnosis. According to the news agency Xinhua, the rate of infertility in China rose from a meagre 3% in the year 1990 to 12.5% in 2010. In India as well, the rate of infertility had reached 10% by 2013, according to the Times of India, a leading national daily in the country.
Along with these factors, technological advancements and the introduction of high precision and accurate preimplantation genetic diagnosis techniques have also significantly benefitted the Asia preimplantation genetic diagnosis market in the past years. Some of the major companies in the market are Quest Diagnostics Incorporated, Genea Limited, Genesis Genetics, Laboratory Corporation of America Holdings, PerkinElmer, Inc., Illumina, Inc., Reprogenetics, Reproductive Genetics Innovations LLC, and Natera, Inc.